OptimizeRx OPRX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $6.84M+144% | $5.13M+126% | $34K+100% | -$9.87M+44.9% | -$15.41M+14.7% | ||
| $4.3M-1.4% | $4.33M-0.1% | $4.34M+2.4% | $4.36M+20.6% | $4.36M+44.9% | ||
| $7.23M-27.7% | $6.96M-39.3% | $7.94M-28.8% | $8.59M-27.0% | $10M-19.1% | ||
| -$1.87M-713% | -$1.21M-29.8% | $1.78M+138% | $1.19M+124% | -$230K+94.0% | ||
| $1.29M+56.7% | $1.11M+33.1% | $1.07M+79.2% | $1.08M+130% | $826K+143% | ||
| $0-100% | $0-100% | $77K-75.9% | $76K-86.4% | $76K-88.7% | ||
| —— | —— | —— | —— | $3.05M— | ||
| —— | —— | —— | -$998K-709% | $1.72M+206% | ||
| —— | —— | —— | $7.46M+5,382% | $2.27M+60.1% | ||
| —— | —— | —— | -$1.31M— | -$85K— | ||
| —— | —— | —— | —— | $337.5K— | ||
| —— | —— | -$3.04M— | -$109K— | -$754K— | ||
| —— | —— | $15K— | $9K— | —— | ||
| $14.38M+117% | $18.72M+283% | $11.83M+855% | $10.41M— | $6.64M— | ||
| $52K-51.4% | $58K-48.2% | $64K-36.0% | $72K-37.6% | $107K+18.3% | ||
| $131K+134% | $68K+115% | -$258K+99.0% | -$340K+98.8% | -$381K+98.4% | ||
| $10.19M+155% | $8M+100% | $8M+154% | $8M+201% | $4M+54.6% | ||
| —— | —— | —— | $448K— | $858K— | ||
| -$10.92M-125% | -$8.8M-79.1% | -$8.17M-124% | -$8.45M-125% | -$4.86M-118% | ||
| $3.6M+158% | $9.99M+2,215% | $3.39M— | $1.63M— | $1.4M— | ||
| $3.86M-35.4% | $4.18M-32.5% | $5.39M+22.9% | $5.78M+74.3% | $5.97M+164% | ||
| $1.85M+1,223% | $1.84M+1,043% | $1.25M+10,300% | $1.14M+749% | $140K+146% | ||
| $1.29M+56.7% | $1.11M+33.1% | $1.07M+79.2% | $1.08M+130% | $826K+143% | ||
| —— | $368K-95.1% | $2.15M— | $3.93M— | $5.71M— | ||
| —— | —— | —— | $7.46M— | $2.27M— | ||
| —— | —— | -$3.04M— | -$109K— | -$754K— | ||
| -$1.87M-151% | -$1.21M+16.2% | -$3.07M— | -$416K— | -$744K— | ||
| —— | $250K0.0% | $250K— | $250K— | $250K— | ||
| —— | —— | $15K— | $9K— | —— | ||
| —— | —— | —— | -$1.31M— | -$85K— | ||
| —— | —— | —— | —— | —— | ||
| $0-100% | $0-100% | $77K-75.9% | $76K-86.4% | $76K-88.7% | ||
| —— | —— | —— | $268K-51.5% | $274K-61.4% | ||
| $14.33M+120% | $18.66M+291% | $11.76M+806% | $10.34M— | $6.53M— | ||
| $14.33M+120% | $18.66M+291% | $11.76M+806% | $10.34M— | $6.53M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does OptimizeRx generate?
- OptimizeRx (OPRX) generated $14.4M in operating cash flow over the trailing twelve months.
- What is OptimizeRx's free cash flow?
- After $52.0K of capital expenditures, OptimizeRx's free cash flow was $14.3M over the trailing twelve months, up 119.5% year over year.
- Where does OptimizeRx's cash flow data come from?
- Every line is extracted from OptimizeRx's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
